Taylor Martino Rowan is investigating claims of serious health risks, lung injury, and cancer, related to the use of Philips Bi-Level Positive Airway Pressure (Bi-Level PAP), Continuous Positive Airway Pressure (CPAP), and mechanical ventilators. In a major announcement in the middle of June, Philips Respironics issued a recall and field safety notice on 3 to 4 million devices here in the United States.
If you are a patient or family member of a patient who has developed serious health complications from using a machine included in the Philips CPAP recall prior to April 2021, you may be eligible for compensation.
A continuous positive airway pressure machine, more commonly referred to as a CPAP machine, is a medical device that is typically prescribed by physicians to treat sleep apnea disorders. There are several different classifications of sleep apnea, including obstructive sleep apnea, central sleep apnea, and complex sleep apnea syndrome.
For those with sleep apnea or respiratory conditions, CPAP and BiPAP machines work by blowing air into patients’ airways while they are asleep or in need of air. Without the assistance of these machines, some patients are at risk of facing life-endangering conditions, such as heart attacks and strokes. However, the Philips company recalled its breathing machine due to the discovery of toxins in the polyester-based polyurethane foam, which was selected for sound-reducing qualities.
Sound-reducing Foam Liner May Be to Blame.
According to Philips, the issue is related to the polyester-based sound abatement foam component in these devices. The foam component can degrade into toxic particles and/or off-gas chemicals that once inhaled by the user can cause serious health conditions. The potential risks of particulate exposure include headache, irritation, inflammation, respiratory issues, and possible toxic and carcinogenic effects. The potential risks of chemical exposure due to off-gassing include headache, irritation, hypersensitivity, nausea/vomiting, and possible toxic and carcinogenic effects.
Philips estimates that 3 to 4 million devices may be affected by the recall, the majority of which are first-generation DreamStation products sold before April 2021. Patient reports show CPAP cancer is a risk from these Philips machines.